1 / 10

Generalised Pustular Psoriasis market

Generalized Pustular Psoriasis (GPP) is a severe form of skin disorder called psoriasis. GPP is caused by abnormal<br>inflammation.<br>

DelveInsight
Télécharger la présentation

Generalised Pustular Psoriasis market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Generalized Pustular Psoriasis (GPP) 01 Generalized Pustular Psoriasis (GPP) is a severe form of skin disorder called psoriasis. GPP is caused by abnormal inflammation. 02 Mutations occur in several genes, including IL36RN and CARD14. They increase the risk of developing Generalized PustularPsoriasis. IL-36Ra protein produced from the IL36RN gene blocks the activity of specific proteins for not promoting skin inflammation. IL36RN gene mutations involved in GPP reduce the amount of IL-36Ra protein in the skin. 03 04 Generalized Pustular Psoriasis (GPP) is more common in females as compared to males worldwide. • DelveInsight © 2019 | All rights reserved

  2. GPP Epidemiology • Generalized Pustular Psoriasis (GPP) is a rare disease and is the rarest form of psoriasis. In patients with a family history of psoriasis or homozygous mutation of IL36RN, onset age is earlier. • GPP accounts for 0.6% • to 7% of all cases of psoriasis and age of onset is between 3 and 16 years. • GPP prevalence was 1.76 per million in France whereas Japan prevalence was 7.46 per million. GPP prevalence affects 2 per million in Europe and occurs in 0.6 per million in Japan. • DelveInsight © 2019 | All rights reserved

  3. GPP Market Outlook GPP market scenario reveals lack of targeted GPP therapies for cure but there are some symptomatic GPP treatments which are being given to the patients. Disease severity and extent of skin involvement may be helpful to determine GPP treatment. Extensive research and development activities of companies to develop GPP therapies that will create a positive impact GPP market during the forecast period (2019-2028). Current research is focused on the development of biologic therapies targeting IL-1, IL-12/23p40, and IL-17A receptors. Anakinra is a biologic therapy and is an IL-1 receptor antagonist for treating GPP, and gevokizumab is an IL-1β inhibitor for treating GPP patients. Drugs in the clinical trials are expected to propel the growth of GPP drugs market in the upcoming years. • DelveInsight © 2019 | All rights reserved

  4. GPP Emerging Drugs and Companies Drug: ANB019 by AnaptysBio GPP market dynamics is anticipated to change in the coming years owing to the rising awareness of the disease. This provides an opportunity for other companies to enter the market like AnaptysBio and BoehringerIngelheimthat are involved in developing GPP therapies. Drug: BI655130 by BoehringerIngelheim • DelveInsight © 2019 | All rights reserved

  5. Complete Information For complete information on Generalized Pustular Psoriasis Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved • DelveInsight © 2019 | All rights reserved

  6. About DelveInsight Mission 2 1 3 About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  7. Services by DelveInsight PharmDelve Forecasting OpportunityAssessment Consulting ReportStore MarketIntelligence Competitive Analysis Pipeline • DelveInsight © 2019 | All rights reserved

  8. Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved

  9. Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved

More Related